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TauEndothelin-1 and voltage-dependent sodium channels are involved in control and suppression of
neuropathological factors, which contribute to sculpting the neuronal network. We previously dem-
onstrated that veratridine-induced NaV1.7 sodium channel activation caused intracellular calcium
elevation, catecholamine secretion and tau dephosphorylation in adrenal chromafﬁn cells. The
aim of this study was to examine whether endothelin-1 could modulate NaV1.7. Our results indi-
cated that endothelin-1 decreased the protein level of NaV1.7 and the veratridine-induced increase
in intracellular calcium. In addition, it also abolished the veratridine-induced dephosphorylation of
tau and the phosphorylation of glycogen synthase kinase-3b and extracellular signal-regulated
kinase. These ﬁndings suggest that the endothelin-1-induced down-regulation of NaV1.7 diminishes
NaV1.7-related catecholamine secretion and dephosphorylation of tau.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction sues of the peripheral and central nervous system [1–3]. AlthoughVoltage-dependent sodium channels, which are composed of
the principal a-subunit, with or without auxiliary bl- to b4-sub-
unit, are responsible for the initiation and conduction of the action
potential. The a-subunit forms the ion-pore and the toxin binding
sites (e.g., site 1 for tetrodotoxin [TTX]; site 2 for veratridine; site 5
for Ptychodiscus brevis toxin) [1]. A total of nine a-subunits have
been identiﬁed and are encoded by nine different genes [1]. Of
these, NaV1.7, which is derived from gene SCN9A, is widely distrib-
uted in the dorsal root ganglion, sympathetic neuron, olfactory
sensory neuron, hippocampus and cerebral cortex within the tis-NaV1.7 has been explored as a therapeutic target for pain in cases
of inﬂammation, diabetic neuropathy and erythermalgia, recent
studies support the involvement of NaV1.7 in neuronal develop-
ment (e.g., differentiation, axon/neurite growth, axon pathﬁnding,
myelination, synapse formation) and neuroprotective-related sig-
nal transduction [1,4].
The adrenal chromafﬁn cells, which are embryologically derived
from the neural crest, speciﬁcally express NaV1.7 [1]. The sodium
inﬂux that occurs via NaV1.7 causes a calcium inﬂux through the
voltage-dependent calcium channels, which then triggers exocyto-
sis and synthesis of catecholamine [1,5]. In our previous studies,
we demonstrated that activation of the phosphoinositide 3-kinase
(PI3K)–Akt, protein kinase C-a (PKC-a)–extracellular signal-regu-
lated kinase (ERK)/p38 and PI3K–PKC-a–ERK/p38 pathways by
veratridine-induced sodium inﬂux via NaV1.7 converged on the
inhibitory Ser9-phosphorylation of glycogen synthase kinase-3b
(GSK-3b). This resulted in decreased Ser396-phosphorylation of
tau, the major microtubules associated protein in the vertebrate
nervous system that is responsible for promoting axon/neurite
growth, neuronal polarity and myelination [4,6].
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and released by the vascular endothelial cells [7]. Endothelin-1
(ET-1), which is one of three isoforms, acts on sites within the cen-
tral, autonomic and peripheral nervous systems and in particular,
participates in the regulation of neurovascular and neurite actions
[7,8]. Toxic effects on neuronal systems that have been reported for
ET-1 include overactivity of the endothelin system that causes neu-
ronal damage and dysfunction, such as is seen in neurodegenera-
tive disease like Alzheimer’s and Parkinson’s disease [9–11]. At
the present time, however, little is known regarding how endothe-
lin and voltage-dependent sodium channels are mutually interre-
lated on the neuronal cells. In the current study, we show that
the ET-1-induced down-regulation of the NaV1.7 cell surface
expression caused attenuation of the NaV1.7-induced catechol-
amine secretion and dephosphorylation of tau.
2. Materials and methods
2.1. Primary culture of adrenal chromafﬁn cells: treatment with test
compounds
Isolated bovine adrenal chromafﬁn cells were cultured (4  106
per dish, Falcon; 35 mm diameter) in Eagle’s minimum essential
medium containing 2 mM L-glutamine and 10% calf serum under
5% CO2/95% air in a CO2 incubator. Three days (60–62 h) later,
the cells were treated with or without 1–100 nM ET-1 for up to
72 h. Chromafﬁn cells were further puriﬁed by differential plating
[4]. The ET-1-induced decreased level of the NaV1.7 protein was
similar between the puriﬁed and conventional chromafﬁn cells.
Speciﬁcally, ET-1 (1 nM for 48 h) decreased the NaV1.7 protein lev-
els by 32% and 30% in the puriﬁed and conventional chromafﬁn
cells, respectively, when compared to the non-treated cells within
each cell group.
2.2. Intracellular calcium imaging: measurement of calcium
concentration in the cytoplasm
Cells were incubated in the dark for 30 min at room tempera-
ture with the calcium-sensitive ﬂuorescent dye, Fluo-4-AM (DOJ-
INDO, Kumamoto), which produced luminescence induced by
calcium at a wavelength of 488 nm in the cytoplasm. To measure
the calcium concentration in the cytoplasm, the Fluo-4-AM infused
cells that were plated on the 35 mm dish were ﬁxed using Krebs–
Ringer phosphate buffer (KRP) (154 mM NaCl, 5.6 mM KCl, 1.1 mM
MgSO4, 2.2 mM CaCl2, 0.85 mM NaH2PO4, 2.15 mM Na2HPO4 and
5 mM glucose, pH 7.4) with or without the veratridine reﬂux appa-
ratus. The Fluo-4-AM luminescence level was measured using a
Leica DMIRE2 ﬂuorescent microscope (Leica Microsystems,
Wetzlar).
2.3. Catecholamine secretion
Cells were washed with ice-cold KRP, and incubated at 37 C for
5 min in a 1 ml KRP buffer with or without veratridine. The incu-
bated KRP with veratridine was saved and placed in a test tube
for a catecholamine assay that was performed by HPLC [12–14].
2.4. Western blot analysis of NaV1.7, tau, Ser
396-phosphorylated tau,
GSK-3b, Ser9-phosphorylated GSK-3b, ERK1/2, Tyr204-phosphorylated
ERK1/2 and GAPDH
Cells were washed with ice-cold calcium-free phosphate-buf-
fered saline and solubilized in 500 lL of 2 sodium dodecyl sulfate
(SDS) electrophoresis sample buffer (125 mM Tris–HCl [pH 6.8],
20% glycerol, 10% 2-mercaptoethanol, and 4% SDS) at 98 C for3 min. No changes were noted between the non-treated and test
compound-treated cells for the total quantities of cellular proteins,
as measured by the Non-interfering Protein Assay kit. After separa-
tion of the same amounts of proteins (7.0–7.5 lg per lane) by SDS–
7.5% or –12% polyacrylamide gel electrophoresis, the samples were
then transferred onto a Hybond-P nitrocellulose membrane (GE
Healthcare, Piscataway, NJ). The membrane was preincubated with
1% bovine serum albumin in Tween–Tris-buffered saline (10 mM
Tris–HCl [pH 7.4], 150 mM NaCl, and 0.1% Tween-20), and reacted
overnight at 4 C in Can Get Signal Solution-1 (TOYOBO, Osaka)
with mouse or rabbit antibodies (1:2000) against NaV1.7 (Milli-
pore, Billerica, MA), tau (Santa Cruz Biotechnology, Santa Cruz,
CA), Ser396-phosphorylated tau (Cell Signaling Technology, Beverly,
MA), GSK-3b (BD Transduction Laboratories, San Diego, CA), Ser9-
phosphorylated GSK-3b (Cell Signaling Technology, Beverly, MA),
ERK1/2 (Santa Cruz Biotechnology, Santa Cruz, CA), Tyr204-phos-
phorylated ERK1/2 (Santa Cruz Biotechnology, Santa Cruz, CA)
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Milli-
pore, Billerica, MA). After repeated washings, the immunoreactive
bands were reacted in Can Get Signal Solution-2 with horseradish
peroxidase-conjugated anti-mouse or anti-rabbit antibody, visual-
ized by the enhanced chemiluminescent detection system ECL
Plus, and then quantiﬁed by a luminoimage LAS-3000 analyzer
(Fuji Film, Tokyo).
2.5. Immunostaining
For immunocytochemistry, treatment of bovine adrenal chro-
mafﬁn cells with or without ET-1 for 48 h, were grown on glass
coverslips. The cells were ﬁxed in 4% paraformaldehyde for
15 min and washed with phosphate-buffered saline containing
20 mM glycine (buffer A) to quench the aldehyde groups. After per-
meabilization with buffer A for 15 min, cells were treated with
phosphate-buffered saline containing 1% bovine serum albumin.
After 1 h at room temperature, cells were labeled with monoclonal
NaV1.7 antibody for 1 h, washed and stained with the secondary
antibody Alexa Fluor594 Goat Anti-Rabbit (1:1000, Invitrogen,
Carlsbad, CA). The NaV1.7 was detected based on its ﬂuorescence
properties. Samples were rinsed and observed in a Leica DMIRE2
ﬂuorescent microscope.
2.6. Statistical analysis
All experiments were repeated at least three times (mean ± -
S.E.M.). Signiﬁcance (P < 0.05) was determined by either a one-
way or two-way ANOVA with a post hoc mean comparison per-
formed by Newman–Keuls multiple range test. A Student’s t-test
was used when the means of the two groups were compared.
3. Results
3.1. ET-1-induced decrease of NaV1.7 protein level and cell surface
expression
Fig. 1A shows the cells that were treated with or without 1–
100 nM ET-1 for 48 h. The cell lysates were subjected to Western
blot analysis using an antibody against NaV1.7 and GAPDH. GAPDH
did not change after the ET-1 treatment, and thus, served as the
control level. ET-1 decreased the NaV1.7 protein level by 35%,
and the maximal reduction was observed with a concentration of
10 nM. Fig. 1B shows the cells that were incubated with or without
10 nM ET-1 for up to 72 h. ET-1 decreased the NaV1.7 protein level
by 37%. The reduction of NaV1.7 became evident within 24 h of
treatment with 10 nM ET-1, reaching the maximal decrease of
37% at 48 h.
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Fig. 1. ET-1-induced decreases of the total and cell surface NaV1.7. Cells were treated (A) with or without 1–10 nM ET-1 for 48 h or (B) with (+) or without () 10 nM ET-1 for
up to 72 h. The cell lysates were subjected to Western blot analysis using antibodies of NaV1.7 and GAPDH. NaV1.7 protein was quantiﬁed and the levels are shown in the
graphs under the panels. The representative blot shown is typical of the blots seen in the ﬁve independent experiments that exhibited similar results. Immunoreactivities
were quantiﬁed by the luminoimage analyzer. A value of 100% represents the NaV1.7 level that was obtained in the non-treated cells (A) at 48 h or (B) at each incubation time.
Values are presented as the mean ± S.E.M. (n = 5). (C) Representative confocal images of the chromafﬁn cells that were exposed to the cell surface NaV1.7 protein and then
immunostained with the secondary antibody Alexa Fluor594 Goat Anti-Rabbit (red). The area in the box beneath the arrowhead was magniﬁed and can be viewed in each
panel. The relative level of NaV1.7 ﬂuorescence intensity/NaV1.7 expression area was quantiﬁed by image analysis software, with the levels presented in the graphs on the
right. Scale bar = 10 lm. Data are presented as the means ± S.E.M. (n = 27). ⁄P < 0.05, compared with non-treated cells.
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the cell surface NaV1.7 in adrenal chromafﬁn cells. Fig. 1C shows
the cells that were incubated with or without 10 nM ET-1 for up
to 48 h. ET-1 reduced the ﬂuorescence intensity of the cell surface
expressed NaV1.7 by 57%.
3.2. Veratridine-induced elevation of intracellular calcium and
catecholamine secretion: reduction by ET-1
To determine whether or not the decreased NaV1.7 caused by
long-lasting stimulation of ET-1 affects the intracellular calcium,
we measured the peak ﬂuorescence intensity after stimulation by
veratridine (a sodium channel activator). A previous study has
shown that veratridine-induced sodium inﬂux via NaV1.7 causes
elevation of the intracellular calcium in adrenal chromafﬁn cells
[4]. Fig. 2A shows the cells that were treated with or without
10 nM ET-1 for 48 h. After infusing the cells with Fluo-4 AM, they
were subjected to the ﬂuorescence intensity of the Green Fluores-
cent Protein analysis. Veratridine increased the intensity by 133%in the non-treated cells. In the ET-1-treated cells, the veratridine-
induced the intensity was reduced by 45%, compared with the
non-treated cells.
It has been demonstrated that calcium inﬂux via the voltage-
dependent calcium channel causes catecholamine secretion in
the adrenal chromafﬁn cells [12–14]. Fig. 2B and E shows that
ET-1 decreased the veratridine-induced catecholamine secretion
by 24%, whereas ET-1 did not change the catecholamine contents.
The maximal reduction of catecholamine secretion was observed
with a concentration of 1 nM. As seen in Fig. 2C and D, a more de-
tailed analysis of the catecholamine secretion revealed that ET-1
also reduced the veratridine-induced noradrenaline and adrenaline
secretion.
To evaluate whether ET-1 exclusively inﬂuenced NaV1.7, we
used nicotine in place of veratridine to stimulate the adrenal chro-
mafﬁn cells. In a previous study, we observed that the nicotine-in-
duced sodium inﬂux was abolished by a nicotinic receptor
antagonist, but not by TTX, which does abrogate the veratridine-in-
duced sodium inﬂux. Therefore, these results suggested that the
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Fig. 2. Veratridine-induced elevation of intracellular calcium and catecholamine secretion: attenuated by ET-1. Cells were treated with or without 10 nM ET-1 for 48 h in the
culture medium and then loaded with the calcium ﬂuorescence probe Fluo 4-AM (green) for 30 min. At each of the designated observation time points, all of the ET-1-treated
cells were then washed. To measure the intracellular calcium concentration, the cells were incubated in KRP buffer for an arbitrary time up to the peak intensity in the
presence of DMSO or veratridine. The Fluo 4-AM ﬂuorescence intensity level at the peak was quantiﬁed by image analysis software, with the levels shown in the graphs on the
right side. Scale bar = 10 lm. Data are presented as the means ± S.E.M. (n = 21). ⁄P < 0.05, compared with DMSO-treated cells within each cell group. #P < 0.05, compared with
veratridine only-treated cells. Cells were treated with or without 10 nM ET-1 for 48 h in the culture medium and then washed at their assigned times. To measure (B)
catecholamine, (C) noradrenaline or (D) adrenaline secretion, all of the cells were incubated for 5 min with or without veratridine (F) in the presence or absence of TTX, and
with or without nicotine. (E) No changes were noted for the ET-1-induced catecholamine contents in the cells. The basal values at 37 C in the absence of veratridine were not
changed by ET-1 treatment, and were subtracted from the data. All values were presented as the mean ± S.E.M. (n = 7). ⁄P < 0.05, compared with ET-1-non-treated cells within
each cell group.
T. Nemoto et al. / FEBS Letters 587 (2013) 898–905 901nicotine-induced sodium inﬂux passed via a nicotinic receptor-
associated non-selective cation channel, which led to a calcium in-
ﬂux via a voltage-dependent calcium channel and the subsequent
catecholamine secretion [12–14].
In the present study, cells were treated with or without
10 nM ET-1 for 48 h, and then stimulated with or without
10 lM nicotine for 5 min prior to the measurement of the cate-
cholamine secretion. Fig. 2F shows that there was no change in
the nicotine-induced catecholamine secretion observed between
the non-treated and ET-1-treated cells. Furthermore, TTX abro-
gated the veratridine-induced catecholamine secretion in the
two cells groups (Fig. 2F).3.3. Veratridine-induced phosphorylations of GSK-3b and ERKl/2, and
the dephosphorylation of tau: abolished by ET-1 treatment
Our previous studies demonstrated that the veratridine-in-
duced sodium inﬂux via NaV1.7 triggered a calcium inﬂux via the
calcium channels in the adrenal chromafﬁn cells. This then led to
the activation of the phospholipase C (PLC)–PKC-a–ERK/p38, the
PI3K–Akt and the PI3K–PLC pathways. These parallel pathways
subsequently converged on the Ser9-phosphorylation of GSK-3b,
which led to a decrease of the Ser396-phosphorylation of tau
[4,6]. In our present study, treatment with 10 nM ET-1 for 48 h
both abolished the veratridine-induced decrease of Ser396-phos-
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phorylated GSK-3b (Fig. 3B) and Tyr204-phosphorylated ERKl/2
(Fig. 3C).
4. Discussion
4.1. ET-1-induced down-regulation of NaV1.7: the role of NaV1.7 in
neuronal development
In the present study, chronic treatment of bovine adrenal chro-
mafﬁn cells with ET-1 down-regulated NaV1.7. Several authors
have previously substantiated that NaV1.7 is highly expressed in
the nerve growth cone and contributes to the differentiation of
the nerve. In particular, one study demonstrated that NaV1.7 was
required within the dorsal root ganglion neuron and the PC12 cells
for both nerve growth factor-induced neurite/axon outgrowth, and
axon growth cone expansion associated with the activation of PLC-
c [15]. In addition, our previous studies of the adrenal chromafﬁncells demonstrated that the insulin and insulin-like growth factor-I
(IGF-I), which are involved in the axon/neurite outgrowth and
growth cone expansion, up-regulated the NaV1.7 expression and
promoted the neurite-like outgrowth [12,13,16–18].
ET-1, however, has been associated with neuronal impairment.
A perivascular microinjection of ET-1 into the adult rat forebrain
was shown to cause axonal and oligodendroglial injury [19]. Dos
Santos et al. [20] additionally demonstrated that microinjection
of ET-1 into the rat spinal nucleus induced axonal damage and
myelin impairment. Overall, these results demonstrated that there
is a relationship between ET-1 and the dysregulation of NaV1.7 that
ultimately causes an abortive effect of the neural construction.
4.2. ET-1-induced attenuation of catecholamine secretion via NaV1.7
We previously reported that the enhancement of catecholamine
secretion due to up-regulation of NaV1.7 expression was induced
by therapeutic drugs and bioactive agents in the adrenal chromaf-
T. Nemoto et al. / FEBS Letters 587 (2013) 898–905 903ﬁn cells [1,12–14,16]. For example, insulin- or IGF-I-caused up-reg-
ulation of NaV1.7 cell surface expression through the inhibitory
Ser9-phosphorylation of GSK-3b resulted in an enhancement of
both the veratridine-induced catecholamine secretion as well as
the enhanced calcium inﬂux via the voltage-dependent calcium
channels [12,13]. In addition, lysophosphatidic acid, which partic-
ularly promotes neuronal development (e.g., neurogenesis, neuro-
nal migration, neuritogenesis, and myelination), also increased the
NaV1.7 expression through the lysophosphatidic acid1 receptor–
Rho–Rho kinase pathway without causing any changes in the so-
dium current properties, such as inducing enhancements of the
veratridine-induced sodium inﬂux, calcium inﬂux, or catechol-
amine secretion [16].
Although ET-1 at least enhanced activities of the TTX-resistant
sodium channel such as NaVl.8 and NaVl.9 in the rat dorsal root
ganglion neurons, it had no effect on the TTX-sensitive sodium
channels, such as NaV1.7 [21]. With regards to the negative regula-
tion by ET-1, Held et al. [22] reported that ET-1 inhibited the volt-
age-dependent L-type calcium channel via activation of the
endothelin-A receptor in the cultured rat cerebellar granule neu-
rons. In PC12 cells, Gardner et al. [23] also reported that even
though ET-1 modulated the release of ATP via the endothelin-B
receptor and attenuated the calcium inﬂux via the L-type calcium
channels, it did not have any effect on the catecholamine secretion.
In the rat anterior hypothalamus, Di Nunzio et al. [24] reported
that not only ET-1, but also ET-3 binds to the endothelin-B recep-
tor-G protein complex, which causes a decreased noradrenaline
secretion via the NOS–cGMP–PKG–GABAA-receptor [24].
In contrast to the Di Nunzio study [24], our present study dem-
onstrated that the decrease of the veratridine-induced catechol-
amine secretion was completely abolished by TTX. In addition,Fig. 4. Down-regulation of NaV1.7 by ET-1: attenuations of NaV1.7–tau dephosphorylatio
NaV1.7 triggers the calcium inﬂux through the calcium channel and the catecholamine
PI3K–PLC pathways that converged on the Ser9-phosphorylation of GSK-3b and decreas
secretion and all of the pathways.we showed that ET-1 did not affect the nicotine-induced catechol-
amine secretion that would normally be triggered by a calcium in-
ﬂux. Thus, these ﬁndings suggest that the decrease of the
veratridine-induced catecholamine secretion on the ET-1-stimu-
lated cells appears to be related to the ET-1-induced reduction of
NaV1.7 on the cell surface.
4.3. ET-1-induced inactivation of the NaV1.7–GSK-3b pathway:
abrogation of tau dephosphorylation
In our present study, besides demonstrating the abolishment of
the veratridine-induced increases of the Tyr204-phosphorylated
ERK1/2 and Ser9-phosphorylated GSK-3b by ET-1, we also showed
that the decrease of phosphorylated tau induced by veratridine
was abrogated by ET-1. Several previous studies have examined
tau’s involvement in microtubule stability, axon/dendrite out-
growth and axon transport [17,25,26]. Tau’s C-terminus has been
shown to interact with tubulin, while tau’s N-terminus has been
shown to bind to Src homology 3 domains of various proteins
(e.g., Src family tyrosine kinases; PI3K; PLC) at the lipid raft of
the plasma membrane [17,26,27]. The lipid raft portion of the
membrane is the point where members of the heteroprotein com-
plex crosstalk during the growth cone development [17,26,27]. All
of these events are regulated by tau’s phosphorylation via GSK-3b
[17,25–28]. In the developing rat hippocampal neurons, more than
80% of tau was highly phosphorylated in the minor processes and
the proximal axon, while only 20% was phosphorylated at the
growth cone [17,28]. Thus, the lower levels of phosphorylated
tau found at the tip of the neurite or growth cone may be the main
point where the neuronal outgrowth and growth cone expansion
are occurring.n and NaV1.7–catecholamine secretion. In the stimulated cells, the sodium inﬂux via
secretion [13]. In addition, this activated the PLC–PKC-a–ERK/p38, PI3K–Akt, and
ed the Ser396-phosphorylation of tau [4]. ET-1 attenuated both the catecholamine
904 T. Nemoto et al. / FEBS Letters 587 (2013) 898–905Tau has also been shown to be associated with neurodegenera-
tive diseases. For example, dysregulated abnormal hyperphosph-
orylation of tau has particularly been noted to form toxic
neuroﬁbrillary tangles inside of the neuronal cells that lead to Alz-
heimer’s disease [17,29,30]. Although treatment of adrenal chro-
mafﬁn cells with insulin increased the tau protein level without
changing the levels of Ser396-phosphorylated tau in our previous
study, we found the ratio of insulin-induced Ser396-phosphoryla-
tion of tau to increased tau was lowered by 74%, during the accel-
eration of the neurite-like outgrowth [17]. In a more recent study,
experimentally-modeled Alzheimer’s disease rats presented with
symptoms of cerebral ischemia after ET-1 injections were per-
formed in the hippocampus [31]. This study additionally showed
that there was an increased neuronal loss and phosphorylated
tau in the hippocampus of these ET-1-injected rats. Taken together,
these results show for the ﬁrst time that the decrease of the tau
phosphorylation that occurs via activation of the NaV1.7–GSK-3b
pathway can be abrogated by ET-1.
Interestingly, the concentration that induced maximal reduc-
tion of veratridine-induced catecholamine secretion (Fig. 2B:
1 nM) was about one order of magnitude lower than that of
NaV1.7 (Fig. 1A: 10 nM). A simple interpretation of these ﬁndings
is that ET-1 reduced veratridine-induced catecholamine secretion
via multiple mechanisms: (i) down-regulation of NaV1.7 and (ii)
other mechanisms. In the present study, ET-1 abolished veratri-
dine-induced phosphorylation of GSK-3b and ERK as well as verat-
ridine-induced dephosphorylation of tau. We have previously
reported that short-term exposure of GSK-3b inhibitors
(SB216763 or SB415286) or ERK inhibitors (PD98059 or U0126)
did not affect catecholamine secretion, although chronic treatment
of these inhibitors enhanced veratridine-induced catecholamine
secretion via up-regulation of NaV1.7 [32–34]. Tau interacts with
tubulin and regulates function of tubulin and microtubules
[17,26]. Neco et al. [35] reported that microtubule disassemblers
or stabilizers have a moderate effect on secretion, only affecting
the release of slow secretory components in bovine adrenal chro-
mafﬁn cells. These correlative ﬁndings imply that ET-1-caused
abrogation of dephosphorylated tau (rightmost lane in Fig. 3A)
have relationship with ET-1-caused attenuation of catecholamine
secretion.
In conclusion, data presented here suggest that ET-1 causes a
down-regulation of NaV1.7 that subsequently may interfere in
the tau dephosphorylation that is induced by the activation of
the NaV1.7–GSK-3b pathway (Fig. 4).
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